The first researcher in the world to discover that aspirin prevents a first attack, Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a comprehensive review in the current issue of the journal Trends in Cardiovascular Medicine. 

Medtronic U.S. Implants Clinical Study Recapturable CoreValve Evolut R

Medtronic Inc. announced the first U.S. implants in the CoreValve Evolut R Clinical Study, which will evaluate  the safety and effectiveness of the new Medtronic CoreValve Evolut R System.

September 11, 2014 — Patients who rely on pacemakers and defibrillators to maintain a normal heart rhythm run the risk of serious health complications if they don’t fully understand how the devices work and what to do when they experience an irregular heartbeat. But a study from Columbia University School of Nursing, published in the Journal of Cardiovascular Nursing, found that 40 percent of patients with these devices had little to no ability to understand information about their cardiac health.

September 11, 2014 — Medtronic announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora noncompliant balloon dilatation catheter. The new device will be featured for the first time in the United States at the Medtronic booth at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

Growing awareness of the harmful effects of radiation exposure is driving the uptake of ultrasound systems, which are radiation free, less expensive, and more versatile than bigger modalities such as magnetic resonance (MR).

Geneia announced a multi-year, strategic partnership with Covidien to help improve the health of and reduce the costs for chronically ill patients. 

U.S.-based Medtronic said it would purchase Ireland-based Covidien for $42.9 billion, combining two of the world's biggest medical device makers and helping Medtronic savings with a headquarters change.

Medtronic Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes — including patient mortality and hospitalizations — in heart failure patients who have cardiac resynchronization therapy (CRT) devices with the AdaptivCRT feature enabled versus patients receiving standard CRT. 

Only 25 percent of interviewed ambulatory providers report that meaningful use is having a positive impact on patient care. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now